β1-blocker in sepsis.

Daisuke HasegawaRyota SatoOsamu Nishida

Published in: Journal of intensive care (2021)

Accumulating evidence is supporting the use of ultrashort-acting β1-blockers while larger randomized controlled trials to clarify the effect of ultrashort-acting β1-blockers are still warranted.

Keyphrases

angiotensin converting enzyme
angiotensin ii
randomized controlled trial
acute kidney injury
intensive care unit
septic shock
systematic review
clinical trial
study protocol
meta analyses